Ayush Secretary Vaidya Rajesh Kotecha gets fourth extension
New Delhi: The Centre on Tuesday extended the tenure of Ayush Secretary
Vaidya Rajesh Kotecha
by a year till June 28, 2026.
This will be his fourth extension on the post. The Appointments Committee of the Cabinet has approved the extension in the tenure of Kotecha, Secretary, Ministry of Ayush, on contract basis for a period of one year beyond June 28, 2025, up to June 28, 2025, on existing terms and conditions, said an order issued by the Personnel Ministry.
Kotecha is among the select group of
lateral entry appointees
who were picked by the Centre as specialists for government departments.
In another departure from the convention of appointing a bureaucrat to the top post, the Centre had in 2017 appointed him as the Secretary of the Ministry of Ayush (
Ayurveda
, Yoga & Naturopathy, Unani, Siddha and Homeopathy).
He was given two-year extensions twice, first in 2020 and then in 2022. In June last year, his tenure was extended by one more year, which was to end on June 28, 2025.
Kotecha, who was a chief consultant at the Chakrapani Ayurveda Clinic in Jaipur, was appointed as a Special Secretary in the
Ayush Ministry
in June 2017. Later, he was appointed as the secretary.
The Ayush Ministry was formed on November 9, 2014, to revive the profound knowledge of ancient systems of medicine with focused attention towards education and research in Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy.
Earlier, the Department of
Indian System of Medicine
and Homoeopathy (ISM&H) formed in 1995 was responsible for the development of these systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
Fourth Covid death reported in state amid rising cases
Karnataka recorded its fourth Covid-related death of the year on Saturday after a 63-year-old man with underlying health conditions succumbed in Bengaluru, bringing renewed attention to the state's ongoing battle with a modest surge in infections. According to the health department, the deceased was being treated for oral cancer and tuberculosis. He had been admitted to a private hospital in the city on May 21 with complaints of general weakness and was undergoing chemotherapy. He died on May 29 due to a jugular vein thrombosis and cancer-associated weight loss, with Covid detected incidentally. The state's active Covid caseload stood at 238 as of Saturday. In the preceding 24 hours, 58 new cases were reported while 53 patients were discharged. Since the beginning of 2025, Karnataka has logged 425 total cases, including 183 recoveries and four fatalities. Testing levels remain steady, with 420 samples examined in the last day — comprising 354 RT-PCR and 66 Rapid Antigen Tests — and a positivity rate of 13.8%. The case fatality rate currently stands at 1.7%, according to official data. Hospital admissions remain limited. Thirteen Covid-positive individuals are undergoing treatment, including one in the ICU of a private hospital. The rest are on isolation beds across both government and private facilities. The majority of patients — 225 — are recovering in home isolation. Health Minister Dinesh Gundu Rao addressed the situation, reassuring the public that the numbers do not warrant panic. 'The current position does not require panic or restrictions. Officials and experts are monitoring continuously. Further decisions will be taken in consultation with the Centre,' he said. The government has stepped up its medical inventory, ensuring the availability of 2,500 rapid antigen test kits, 1.3 lakh RNA extraction kits, 5,000 RT-PCR kits, and two lakh viral transport medium (VTM) kits. An additional 5,000 RT-PCR kits are also being procured to support continued testing over the next month. Weekly meetings of the state's technical advisory committee have been mandated to track trends and respond to developments. On the possibility of imposing travel restrictions amid rising cases in neighbouring Kerala, the minister clarified that no such move is under consideration. 'Such measures, if at all needed, will be decided by the Centre after inputs from the state,' he said.
Mint
6 hours ago
- Mint
India seeks financial details of pharmaceutical marketing practices, industry caught in a bind
The Centre has asked pharma companies for details of expenditure on marketing in the last one year, putting the industry in a bind. The details sought by the Department of Pharmaceuticals (DoP) has to be submitted by 31 July, failing which action will be taken against pharmaceutical Union government is keeping a close watch on the marketing practice of pharmaceutical companies amid reports of these companies continuing to offer a range of freebies to doctors, despite the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) being implemented to check unethical marketing practices. Also read: Low vaccine stocks in focus as new covid variants spread A communication, dated 29 May, has been issued by the government to all the pharmaceutical associations to fulfil the compliance as per the targeted deadline. 'The department of pharmaceuticals (DoP) has directed for the submission of the self-declaration and disclosure of marketing expenditure under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. The timeline for submissions pertaining to the financial year 2024–25 is now 31st July 2025," said Daara Patel, secretary general at the Indian Drugs Manufacturers Association (IDMA). The self-declaration is a legal undertaking to be filed by company bosses to assure the government that they are not indulging in any unethical marketing practices to promote their products. Also read: India puts big pharma concessions on table as US trade deal nears finish line Patel said that the implementation of the UCPMP guidelines has created a sense of caution and transparency in the marketing practice of the companies which is good for the industry. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance said, 'It is for the first time that such a massive compliance is being done by the pharma companies. The data has to be uploaded on the dedicated portal of the government to make it a standardized practice for the companies for further point of view." 'Our member companies are ready to update the financial details of the pharmaceutical marketing to the government," the industry executive said. The UCPMP was introduced in March last year with an objective to bring about transparency and ensure ethical conduct in the marketing practices of pharmaceutical companies and restrict them from offering freebies such as gifts, travel, hospitality and monetary benefits to doctors for prescribing a particular medicine. According to government data, India is home to approx. 3,000 drug making companies and 10,500 manufacturing units. The industry is projected to reach a value of $130 billion by 2030. Queries sent to the department of pharmaceutical spokesperson remained unanswered till press time. Also read: Govt alert: common antibiotic treatment may be 'life threatening' This entire exercise is being done in the backdrop of the Micro Labs controversy: the makers of Dolo650 mg allegedly offered freebies to doctors during the pandemic to prescribe the anti-fever medicine. Last year in December, DoP, accused Abbvie Healthcare India Pvt. Ltd of breaching the guidelines of the UCPMP by allegedly sponsoring vacations for 30 medical professionals to Monaco and Paris. The company could not be contacted for comment.
Time of India
9 hours ago
- Time of India
IMA Telangana opposes proposed integrated MBBS-BAMS course
Hyderabad: The Central govt's announcement to introduce an integrated medical course combining MBBS (Bachelor of Medicine, Bachelor of Surgery) and BAMS (Bachelor of Ayurvedic Medicine and Surgery) at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, has evoked strong criticism from the medical fraternity in Telangana. Tired of too many ads? go ad free now The idea of the course stems from the National Medical Commission's (NMC) move of introducing modules on AYUSH to promote the integration of modern medicine with homoeopathy and Ayurveda. Typically, it takes five and a half years to complete the MBBS course, including a year of mandatory internship. Dr Dwarkanath Reddy, president, IMA Telangana, said that the integrated course could compromise the rigorous standards of modern medical education as it not only threatens modern medicine but also risks damaging Ayurveda by weakening its core principles. "We recognise the importance of Ayurveda, but mixing it with medicine will not benefit either field as it does not align with the principles of modern medicine. Will a patient be given ayurvedic medicine after a medical surgery? Patients will be the ultimate losers this way as it strips them of their freedom to choose a preferred system of care," he said. Earlier, the Telangana Junior Doctors Association (T-JUDA) called the announcement a "regressive and unscientific move," stating that it sees no public health benefit in the govt's push for "mixopathy," a term coined for the integrated course. Dr J Isaac Newton, president, T-JUDA, said that the new course risks producing inadequately trained practitioners, who can also be called "qualified quacks." "This is because they will lack expertise in either of the two disciplines. We should take the example of China, whose attempt to blend modern medicine with traditional Chinese medicine failed miserably and led to the weakening of its own indigenous system. " Doctors also appealed to practitioners of Ayurvedic medicine to unite in opposing the new policy for the benefit of both doctors and patients.
